The ESMO Congress is a highly influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. https://www.esmo.org/
Several projects in which we collaborated are presented this year in Berlin:
Durvalumab (D) plus tremelimumab (T) in advanced biliary tract carcinoma (BTC) patients (Pts) after failure of platinum-based chemotherapy (CTx): Final results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 phase II trial. Matthieu Delaye et al.
UCPVax plus Nivolumab versus chemotherapy after first line chemoimmunotherapy in patients with advanced non-small cell lung cancer. Olivier Adotevi et al.
Ezabenlimab (BI 754091) and induction mDCF (modified docetaxel, cisplatin, and 5-fluorouracil) followed by adaptive chemoradiotherapy in patients (pts) with stage III squamous cell anal carcinoma (SCAC): final results of the Phase II INTERACT-ION study. Stefano Kim et al.
Nivolumab and ipilimumab in anti-PD1-resistant MSI/dMMR metastatic colorectal cancer: interim analysis of the GERCOR NIPIRESCUE phase II trial. Romain Cohen et al.
Efficacy and safety of two schemes of nivolumab (Nivo) and ipilimumab (Ipi) in MSI/dMMR metastatic colorectal cancer (mCRC): The PRODIGE-74 GERCOR NIPISAFE randomized non-comparative phase II trial. Romain Cohen et al.
Durvalumab (D) +/- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): updated results (EFS and OS) of NEMIO, a phase I/II trial. Constance Thibault et al.
FREDO-ODX: a real-world French study of Oncotype DX® use and clinical outcomes in ER+/HER2− early breast cancer patients. Elsa Curtit et al.
About Sophie PAGET-BAILLY
Sophie Paget-Bailly is a research engineer in epidemiology and clinical research. She passed with honours the East of France inter-region master’s degree in public health and occupational and environmental risks. During the master’s degree’s internship in the Interregional Epidemiology Unit of Bourgogne/Franche-Comté, she realized a quantitative health risk assessment in the context of chemical contamination of groundwater. She defended a PhD in Public Health and Epidemiology in Paris XI University, Doctoral School 420, working in the Centre for Research in Epidemiology and Population Health in Villejuif, France. Her PhD research focused on occupational exposures and head and neck cancer.